Global Immune Checkpoint Inhibitors Market Research Report 2022(Status and Outlook)
Global Immune Checkpoint Inhibitors Market Research Report 2022(Status and Outlook)
Abstract
Report Overview
Immune checkpoints are proteins that play an important role in regulating the immune system. In cancer, the immune checkpoints are activated to suppress the anti-tumor activity of the immune system thereby suppressing the immune response against the cancer cells. The study of these proteins and pathways has led to the development of a number of immune checkpoint inhibitors as therapies against cancer. Initial preclinical studies showed that antibody blockade of the immune checkpoint molecule CTLA-4 resulted in successful anti-tumor immune responses in the murine cancer models. This was then followed by studies targeting the PD-1/PD-L1 pathway. Ipilimumab and Yervoy were the first immune checkpoint inhibitors introduced in the market. With the promising results of Yervoy, several anti-PD-1 and anti-PD-L1 antibodies have been developed. Although there are number of other checkpoints that have been studied, such as LAG-3 and TIM-3, the only approved immune checkpoint inhibitors include CTLA-4, PD-1 and PD-L1.
The Global Immune Checkpoint Inhibitors Market Size was estimated at USD 12563.81 million in 2021 and is projected to reach USD 36071.13 million by 2028, exhibiting a CAGR of 16.26% during the forecast period.
Bosson Research’s latest report provides a deep insight into the global Immune Checkpoint Inhibitors market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Immune Checkpoint Inhibitors Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Immune Checkpoint Inhibitors market in any manner.
Global Immune Checkpoint Inhibitors Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
•Bristol Myer Squibb
•AstraZeneca
•Merck
•Roche / Genentech
•Ono Pharmaceutical
•Regeneron
•Innovent
•Hengrui Medicine
•Junshi Biosciences
Market Segmentation (by Type)
•PD-1/PD-L1
•CTLA-4
Market Segmentation (by Application)
•Lung Cancer
•Colorectal Cancer
•Breast Cancer
•Prostate Cancer
•Melanoma
•Blood Cancer
•Other
Geographic Segmentation
• North America (USA, Canada, Mexico)
• Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
• Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
• South America (Brazil, Argentina, Columbia, Rest of South America)
• The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Key Benefits of This Market Research:
• Industry drivers, restraints, and opportunities covered in the study
• Neutral perspective on the market performance
• Recent industry trends and developments
• Competitive landscape & strategies of key players
• Potential & niche segments and regions exhibiting promising growth covered
• Historical, current, and projected market size, in terms of value
• In-depth analysis of the Immune Checkpoint Inhibitors Market
• Overview of the regional outlook of the Immune Checkpoint Inhibitors Market:
Key Reasons to Buy this Report:
• Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
• This enables you to anticipate market changes to remain ahead of your competitors
• You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
• The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
• Provision of market value (USD Billion) data for each segment and sub-segment
• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
• Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
• The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
• Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis
• Provides insight into the market through Value Chain
• Market dynamics scenario, along with growth opportunities of the market in the years to come
• 6-month post-sales analyst support
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Note: this report may need to undergo a final check or review and this could take about 48 hours.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Immune Checkpoint Inhibitors Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the Market's Competitive Landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.
Chapter 12 is the main points and conclusions of the report.
Content
TABLE OF CONTENTS
1 Research Methodology and Statistical Scope
1.1 Market Definition and Statistical Scope of Immune Checkpoint Inhibitors
1.2 Key Market Segments
1.2.1 Immune Checkpoint Inhibitors Segment by Type
1.2.2 Immune Checkpoint Inhibitors Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 Immune Checkpoint Inhibitors Market Overview
2.1 Global Market Overview
2.1.1 Global Immune Checkpoint Inhibitors Market Size (M USD) Estimates and Forecasts (2017-2028)
2.1.2 Global Immune Checkpoint Inhibitors Sales Estimates and Forecasts (2017-2028)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 Immune Checkpoint Inhibitors Market Competitive Landscape
3.1 Global Immune Checkpoint Inhibitors Sales by Manufacturers (2017-2022)
3.2 Global Immune Checkpoint Inhibitors Revenue Market Share by Manufacturers (2017-2022)
3.3 Immune Checkpoint Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Immune Checkpoint Inhibitors Average Price by Manufacturers (2017-2022)
3.5 Manufacturers Immune Checkpoint Inhibitors Sales Sites, Area Served, Product Type
3.6 Immune Checkpoint Inhibitors Market Competitive Situation and Trends
3.6.1 Immune Checkpoint Inhibitors Market Concentration Rate
3.6.2 Global 5 and 10 Largest Immune Checkpoint Inhibitors Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 Immune Checkpoint Inhibitors Industry Chain Analysis
4.1 Immune Checkpoint Inhibitors Industry Chain Analysis
4.2 Market Overview and Market Concentration Analysis of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 The Development and Dynamics of Immune Checkpoint Inhibitors Market
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 Immune Checkpoint Inhibitors Market Segmentation by Type
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Immune Checkpoint Inhibitors Sales Market Share by Type (2017-2022)
6.3 Global Immune Checkpoint Inhibitors Market Size Market Share by Type (2017-2022)
6.4 Global Immune Checkpoint Inhibitors Price by Type (2017-2022)
7 Immune Checkpoint Inhibitors Market Segmentation by Application
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Immune Checkpoint Inhibitors Market Sales by Application (2017-2022)
7.3 Global Immune Checkpoint Inhibitors Market Size (M USD) by Application (2017-2022)
7.4 Global Immune Checkpoint Inhibitors Sales Growth Rate by Application (2017-2022)
8 Immune Checkpoint Inhibitors Market Segmentation by Region
8.1 Global Immune Checkpoint Inhibitors Sales by Region
8.1.1 Global Immune Checkpoint Inhibitors Sales by Region
8.1.2 Global Immune Checkpoint Inhibitors Sales Market Share by Region
8.2 North America
8.2.1 North America Immune Checkpoint Inhibitors Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Immune Checkpoint Inhibitors Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Immune Checkpoint Inhibitors Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Immune Checkpoint Inhibitors Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Immune Checkpoint Inhibitors Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 Key Companies Profiled
9.1 Bristol Myer Squibb
9.1.1 Bristol Myer Squibb Immune Checkpoint Inhibitors Basic Information
9.1.2 Bristol Myer Squibb Immune Checkpoint Inhibitors Product Overview
9.1.3 Bristol Myer Squibb Immune Checkpoint Inhibitors Product Market Performance
9.1.4 Bristol Myer Squibb Business Overview
9.1.5 Bristol Myer Squibb Immune Checkpoint Inhibitors SWOT Analysis
9.1.6 Bristol Myer Squibb Recent Developments
9.2 AstraZeneca
9.2.1 AstraZeneca Immune Checkpoint Inhibitors Basic Information
9.2.2 AstraZeneca Immune Checkpoint Inhibitors Product Overview
9.2.3 AstraZeneca Immune Checkpoint Inhibitors Product Market Performance
9.2.4 AstraZeneca Business Overview
9.2.5 AstraZeneca Immune Checkpoint Inhibitors SWOT Analysis
9.2.6 AstraZeneca Recent Developments
9.3 Merck
9.3.1 Merck Immune Checkpoint Inhibitors Basic Information
9.3.2 Merck Immune Checkpoint Inhibitors Product Overview
9.3.3 Merck Immune Checkpoint Inhibitors Product Market Performance
9.3.4 Merck Business Overview
9.3.5 Merck Immune Checkpoint Inhibitors SWOT Analysis
9.3.6 Merck Recent Developments
9.4 Roche / Genentech
9.4.1 Roche / Genentech Immune Checkpoint Inhibitors Basic Information
9.4.2 Roche / Genentech Immune Checkpoint Inhibitors Product Overview
9.4.3 Roche / Genentech Immune Checkpoint Inhibitors Product Market Performance
9.4.4 Roche / Genentech Business Overview
9.4.5 Roche / Genentech Immune Checkpoint Inhibitors SWOT Analysis
9.4.6 Roche / Genentech Recent Developments
9.5 Ono Pharmaceutical
9.5.1 Ono Pharmaceutical Immune Checkpoint Inhibitors Basic Information
9.5.2 Ono Pharmaceutical Immune Checkpoint Inhibitors Product Overview
9.5.3 Ono Pharmaceutical Immune Checkpoint Inhibitors Product Market Performance
9.5.4 Ono Pharmaceutical Business Overview
9.5.5 Ono Pharmaceutical Immune Checkpoint Inhibitors SWOT Analysis
9.5.6 Ono Pharmaceutical Recent Developments
9.6 Regeneron
9.6.1 Regeneron Immune Checkpoint Inhibitors Basic Information
9.6.2 Regeneron Immune Checkpoint Inhibitors Product Overview
9.6.3 Regeneron Immune Checkpoint Inhibitors Product Market Performance
9.6.4 Regeneron Business Overview
9.6.5 Regeneron Recent Developments
9.7 Innovent
9.7.1 Innovent Immune Checkpoint Inhibitors Basic Information
9.7.2 Innovent Immune Checkpoint Inhibitors Product Overview
9.7.3 Innovent Immune Checkpoint Inhibitors Product Market Performance
9.7.4 Innovent Business Overview
9.7.5 Innovent Recent Developments
9.8 Hengrui Medicine
9.8.1 Hengrui Medicine Immune Checkpoint Inhibitors Basic Information
9.8.2 Hengrui Medicine Immune Checkpoint Inhibitors Product Overview
9.8.3 Hengrui Medicine Immune Checkpoint Inhibitors Product Market Performance
9.8.4 Hengrui Medicine Business Overview
9.8.5 Hengrui Medicine Recent Developments
9.9 Junshi Biosciences
9.9.1 Junshi Biosciences Immune Checkpoint Inhibitors Basic Information
9.9.2 Junshi Biosciences Immune Checkpoint Inhibitors Product Overview
9.9.3 Junshi Biosciences Immune Checkpoint Inhibitors Product Market Performance
9.9.4 Junshi Biosciences Business Overview
9.9.5 Junshi Biosciences Recent Developments
10 Immune Checkpoint Inhibitors Market Forecast by Region
10.1 Global Immune Checkpoint Inhibitors Market Size Forecast
10.2 Global Immune Checkpoint Inhibitors Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Immune Checkpoint Inhibitors Market Size Forecast by Country
10.2.3 Asia Pacific Immune Checkpoint Inhibitors Market Size Forecast by Region
10.2.4 South America Immune Checkpoint Inhibitors Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Immune Checkpoint Inhibitors by Country
11 Forecast Market by Type and by Application (2022-2028)
11.1 Global Immune Checkpoint Inhibitors Market Forecast by Type (2022-2028)
11.1.1 Global Forecasted Sales of Immune Checkpoint Inhibitors by Type (2022-2028)
11.1.2 Global Immune Checkpoint Inhibitors Market Size Forecast by Type (2022-2028)
11.1.3 Global Forecasted Price of Immune Checkpoint Inhibitors by Type (2022-2028)
11.2 Global Immune Checkpoint Inhibitors Market Forecast by Application (2022-2028)
11.2.1 Global Immune Checkpoint Inhibitors Sales (K Units) Forecast by Application
11.2.2 Global Immune Checkpoint Inhibitors Market Size (M USD) Forecast by Application (2022-2028)
12 Conclusion and Key Findings
Immune checkpoints are proteins that play an important role in regulating the immune system. In cancer, the immune checkpoints are activated to suppress the anti-tumor activity of the immune system thereby suppressing the immune response against the cancer cells. The study of these proteins and pathways has led to the development of a number of immune checkpoint inhibitors as therapies against cancer. Initial preclinical studies showed that antibody blockade of the immune checkpoint molecule CTLA-4 resulted in successful anti-tumor immune responses in the murine cancer models. This was then followed by studies targeting the PD-1/PD-L1 pathway. Ipilimumab and Yervoy were the first immune checkpoint inhibitors introduced in the market. With the promising results of Yervoy, several anti-PD-1 and anti-PD-L1 antibodies have been developed. Although there are number of other checkpoints that have been studied, such as LAG-3 and TIM-3, the only approved immune checkpoint inhibitors include CTLA-4, PD-1 and PD-L1.
The Global Immune Checkpoint Inhibitors Market Size was estimated at USD 12563.81 million in 2021 and is projected to reach USD 36071.13 million by 2028, exhibiting a CAGR of 16.26% during the forecast period.
Bosson Research’s latest report provides a deep insight into the global Immune Checkpoint Inhibitors market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Immune Checkpoint Inhibitors Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Immune Checkpoint Inhibitors market in any manner.
Global Immune Checkpoint Inhibitors Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
•Bristol Myer Squibb
•AstraZeneca
•Merck
•Roche / Genentech
•Ono Pharmaceutical
•Regeneron
•Innovent
•Hengrui Medicine
•Junshi Biosciences
Market Segmentation (by Type)
•PD-1/PD-L1
•CTLA-4
Market Segmentation (by Application)
•Lung Cancer
•Colorectal Cancer
•Breast Cancer
•Prostate Cancer
•Melanoma
•Blood Cancer
•Other
Geographic Segmentation
• North America (USA, Canada, Mexico)
• Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
• Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
• South America (Brazil, Argentina, Columbia, Rest of South America)
• The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Key Benefits of This Market Research:
• Industry drivers, restraints, and opportunities covered in the study
• Neutral perspective on the market performance
• Recent industry trends and developments
• Competitive landscape & strategies of key players
• Potential & niche segments and regions exhibiting promising growth covered
• Historical, current, and projected market size, in terms of value
• In-depth analysis of the Immune Checkpoint Inhibitors Market
• Overview of the regional outlook of the Immune Checkpoint Inhibitors Market:
Key Reasons to Buy this Report:
• Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
• This enables you to anticipate market changes to remain ahead of your competitors
• You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
• The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
• Provision of market value (USD Billion) data for each segment and sub-segment
• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
• Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
• The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
• Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis
• Provides insight into the market through Value Chain
• Market dynamics scenario, along with growth opportunities of the market in the years to come
• 6-month post-sales analyst support
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Note: this report may need to undergo a final check or review and this could take about 48 hours.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Immune Checkpoint Inhibitors Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the Market's Competitive Landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.
Chapter 12 is the main points and conclusions of the report.
1 Research Methodology and Statistical Scope
1.1 Market Definition and Statistical Scope of Immune Checkpoint Inhibitors
1.2 Key Market Segments
1.2.1 Immune Checkpoint Inhibitors Segment by Type
1.2.2 Immune Checkpoint Inhibitors Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 Immune Checkpoint Inhibitors Market Overview
2.1 Global Market Overview
2.1.1 Global Immune Checkpoint Inhibitors Market Size (M USD) Estimates and Forecasts (2017-2028)
2.1.2 Global Immune Checkpoint Inhibitors Sales Estimates and Forecasts (2017-2028)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 Immune Checkpoint Inhibitors Market Competitive Landscape
3.1 Global Immune Checkpoint Inhibitors Sales by Manufacturers (2017-2022)
3.2 Global Immune Checkpoint Inhibitors Revenue Market Share by Manufacturers (2017-2022)
3.3 Immune Checkpoint Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Immune Checkpoint Inhibitors Average Price by Manufacturers (2017-2022)
3.5 Manufacturers Immune Checkpoint Inhibitors Sales Sites, Area Served, Product Type
3.6 Immune Checkpoint Inhibitors Market Competitive Situation and Trends
3.6.1 Immune Checkpoint Inhibitors Market Concentration Rate
3.6.2 Global 5 and 10 Largest Immune Checkpoint Inhibitors Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 Immune Checkpoint Inhibitors Industry Chain Analysis
4.1 Immune Checkpoint Inhibitors Industry Chain Analysis
4.2 Market Overview and Market Concentration Analysis of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 The Development and Dynamics of Immune Checkpoint Inhibitors Market
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 Immune Checkpoint Inhibitors Market Segmentation by Type
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Immune Checkpoint Inhibitors Sales Market Share by Type (2017-2022)
6.3 Global Immune Checkpoint Inhibitors Market Size Market Share by Type (2017-2022)
6.4 Global Immune Checkpoint Inhibitors Price by Type (2017-2022)
7 Immune Checkpoint Inhibitors Market Segmentation by Application
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Immune Checkpoint Inhibitors Market Sales by Application (2017-2022)
7.3 Global Immune Checkpoint Inhibitors Market Size (M USD) by Application (2017-2022)
7.4 Global Immune Checkpoint Inhibitors Sales Growth Rate by Application (2017-2022)
8 Immune Checkpoint Inhibitors Market Segmentation by Region
8.1 Global Immune Checkpoint Inhibitors Sales by Region
8.1.1 Global Immune Checkpoint Inhibitors Sales by Region
8.1.2 Global Immune Checkpoint Inhibitors Sales Market Share by Region
8.2 North America
8.2.1 North America Immune Checkpoint Inhibitors Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Immune Checkpoint Inhibitors Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Immune Checkpoint Inhibitors Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Immune Checkpoint Inhibitors Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Immune Checkpoint Inhibitors Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 Key Companies Profiled
9.1 Bristol Myer Squibb
9.1.1 Bristol Myer Squibb Immune Checkpoint Inhibitors Basic Information
9.1.2 Bristol Myer Squibb Immune Checkpoint Inhibitors Product Overview
9.1.3 Bristol Myer Squibb Immune Checkpoint Inhibitors Product Market Performance
9.1.4 Bristol Myer Squibb Business Overview
9.1.5 Bristol Myer Squibb Immune Checkpoint Inhibitors SWOT Analysis
9.1.6 Bristol Myer Squibb Recent Developments
9.2 AstraZeneca
9.2.1 AstraZeneca Immune Checkpoint Inhibitors Basic Information
9.2.2 AstraZeneca Immune Checkpoint Inhibitors Product Overview
9.2.3 AstraZeneca Immune Checkpoint Inhibitors Product Market Performance
9.2.4 AstraZeneca Business Overview
9.2.5 AstraZeneca Immune Checkpoint Inhibitors SWOT Analysis
9.2.6 AstraZeneca Recent Developments
9.3 Merck
9.3.1 Merck Immune Checkpoint Inhibitors Basic Information
9.3.2 Merck Immune Checkpoint Inhibitors Product Overview
9.3.3 Merck Immune Checkpoint Inhibitors Product Market Performance
9.3.4 Merck Business Overview
9.3.5 Merck Immune Checkpoint Inhibitors SWOT Analysis
9.3.6 Merck Recent Developments
9.4 Roche / Genentech
9.4.1 Roche / Genentech Immune Checkpoint Inhibitors Basic Information
9.4.2 Roche / Genentech Immune Checkpoint Inhibitors Product Overview
9.4.3 Roche / Genentech Immune Checkpoint Inhibitors Product Market Performance
9.4.4 Roche / Genentech Business Overview
9.4.5 Roche / Genentech Immune Checkpoint Inhibitors SWOT Analysis
9.4.6 Roche / Genentech Recent Developments
9.5 Ono Pharmaceutical
9.5.1 Ono Pharmaceutical Immune Checkpoint Inhibitors Basic Information
9.5.2 Ono Pharmaceutical Immune Checkpoint Inhibitors Product Overview
9.5.3 Ono Pharmaceutical Immune Checkpoint Inhibitors Product Market Performance
9.5.4 Ono Pharmaceutical Business Overview
9.5.5 Ono Pharmaceutical Immune Checkpoint Inhibitors SWOT Analysis
9.5.6 Ono Pharmaceutical Recent Developments
9.6 Regeneron
9.6.1 Regeneron Immune Checkpoint Inhibitors Basic Information
9.6.2 Regeneron Immune Checkpoint Inhibitors Product Overview
9.6.3 Regeneron Immune Checkpoint Inhibitors Product Market Performance
9.6.4 Regeneron Business Overview
9.6.5 Regeneron Recent Developments
9.7 Innovent
9.7.1 Innovent Immune Checkpoint Inhibitors Basic Information
9.7.2 Innovent Immune Checkpoint Inhibitors Product Overview
9.7.3 Innovent Immune Checkpoint Inhibitors Product Market Performance
9.7.4 Innovent Business Overview
9.7.5 Innovent Recent Developments
9.8 Hengrui Medicine
9.8.1 Hengrui Medicine Immune Checkpoint Inhibitors Basic Information
9.8.2 Hengrui Medicine Immune Checkpoint Inhibitors Product Overview
9.8.3 Hengrui Medicine Immune Checkpoint Inhibitors Product Market Performance
9.8.4 Hengrui Medicine Business Overview
9.8.5 Hengrui Medicine Recent Developments
9.9 Junshi Biosciences
9.9.1 Junshi Biosciences Immune Checkpoint Inhibitors Basic Information
9.9.2 Junshi Biosciences Immune Checkpoint Inhibitors Product Overview
9.9.3 Junshi Biosciences Immune Checkpoint Inhibitors Product Market Performance
9.9.4 Junshi Biosciences Business Overview
9.9.5 Junshi Biosciences Recent Developments
10 Immune Checkpoint Inhibitors Market Forecast by Region
10.1 Global Immune Checkpoint Inhibitors Market Size Forecast
10.2 Global Immune Checkpoint Inhibitors Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Immune Checkpoint Inhibitors Market Size Forecast by Country
10.2.3 Asia Pacific Immune Checkpoint Inhibitors Market Size Forecast by Region
10.2.4 South America Immune Checkpoint Inhibitors Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Immune Checkpoint Inhibitors by Country
11 Forecast Market by Type and by Application (2022-2028)
11.1 Global Immune Checkpoint Inhibitors Market Forecast by Type (2022-2028)
11.1.1 Global Forecasted Sales of Immune Checkpoint Inhibitors by Type (2022-2028)
11.1.2 Global Immune Checkpoint Inhibitors Market Size Forecast by Type (2022-2028)
11.1.3 Global Forecasted Price of Immune Checkpoint Inhibitors by Type (2022-2028)
11.2 Global Immune Checkpoint Inhibitors Market Forecast by Application (2022-2028)
11.2.1 Global Immune Checkpoint Inhibitors Sales (K Units) Forecast by Application
11.2.2 Global Immune Checkpoint Inhibitors Market Size (M USD) Forecast by Application (2022-2028)
12 Conclusion and Key Findings
Related Report
